Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α-LGR5 antibody
- Development stage
- Preclinical
- Lead developer
- AdcoTx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
α-LGR5 antibody is a preclinical-stage, highly specific monoclonal antibody raised against the N-terminal extracellular domain of human leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a well-validated stem cell and cancer stem cell marker. Developed by researchers at the University of Cambridge and spun out into AdcoTx, the antibody has been engineered into multiple therapeutic formats, including an antibody-drug conjugate (α-LGR5-ADC) carrying monomethyl auristatin E (MMAE), a bispecific T-cell engager (α-LGR5/α-CD3 BiTE), and chimeric antigen receptor (CAR) T and NK cells. α-LGR5 antibody and its derivatives have demonstrated potent preclinical efficacy in vitro and in vivo against LGR5-expressing malignancies, such as colorectal cancer (CRC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), and pre-B acute lymphoblastic leukemia (pre-B-ALL).
- Other names
- LGR5 antibodyLGR-5 antibodyLGR 5 antibodyLGR5 monoclonal antibodyLGR-5 monoclonal antibodyLGR 5 monoclonal antibodyalpha-LGR5 antibodyalpha-LGR-5 antibodyalpha-LGR 5 antibodyα-LGR5
02
Targets
LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5)
Beyond the preview
Go deeper on α-LGR5 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on α-LGR5 antibody.